Canada's Top 10 Life Science Companies Competition-a program of the Ottawa Life Sciences Council-is an annual national competition sponsored by Borden Ladner Gervais LLP and htx.ca - The Health Technology Exchange. The awards are presented to growth-oriented companies and are chosen by an independent expert panel of Canadian and U.S. venture capitalists. As one of Canada's Top 10, Rimon-along with other competition winners and alumni-will participated in an investment forum series that took place in early 2007 in New York, Boston.

Here are Mike’s musings about the events, and the impact of the success of the clinical trial is making on Rimon’s messaging:

“The Canadian consulates in Boston and New York City hosted the top ten companies that received the award thought the Ottawa Life sciences Council. At both events we each made a formal presentation and had opportunities to meet investment bankers, intuitional VCs, service providers, angel investors, and VCs. The Boston event had 50 people and was tied to a Licensing Executive Society meeting. The New York event was well attended with 150 in attendance. In New York there was a panel and a great informal networking event over cocktails.

We got strong feedback from both presentations. Rimon’s message is simple; the value proposition is clearly laid out. We primarily dwell on the opportunity in these presentations and the science second. We focus on what makes us unique. This approach works well. The Theramer™ concept is immediately appreciated as different. It is a bit “off the wall” – a polymer, a plastic that in drug like. One way to think of a Theramer™ is as a 3-dimensioanal drug. It is one of those different ideas that require validation and demonstration for people to believe. We are getting to that with our clinical data that have produced positive results. We have shown with statistical significance that we can reduce enzyme levels in chronic wounds compared to base line and one of the world’s most successful brands with good co-relation between that inhibition and improved wound bed quality (a precursor to wound healing). We are getting much more positive information than we ever expected from this trial. The clinical trial we have collected validated our strategy of picking an application that would allow us to get into clinical studies fast. The data we have collected from human wounds just could not be replicated even with five times as many animal experiments. So, we plan to continue finding new applications for Theramers™ that validate the technology and get us to clinical trials and on the market as quickly as possible. The Theramer™ concept is a novel idea with great opportunities.”

Click for coverage in Canadian Business.